CD70
| CD70 molecule | |
|---|---|
| Identifiers | |
| Symbol | CD70 |
| Alt. symbols | CD27LG, TNFSF7 |
| Entrez | 970 |
| HUGO | 11937 |
| OMIM | 602840 |
| RefSeq | NM_001252 |
| UniProt | P32970 |
| Other data | |
| Locus | Chr. 19 p13 |
CD70 (Cluster of Differentiation 70) is a ligand for CD27.
Clinical significance
The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes do not express a lot of CD70.[1]
Drug development
ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.[2]
Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.[3]
See also
References
- ↑ Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005). "Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas". Mol. Cancer Ther. 4 (12): 2037–44. doi:10.1158/1535-7163.MCT-05-0253. PMID 16373719.
- ↑ "ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action". arGEN-X. Retrieved 28 February 2015.
- ↑ Seattle Genetics Third Quarter 2013 Financial Report
External links
- CD70 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH)